Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7030900 | 0.98 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2KMT2ANPC1 | |
| SCHEMBL829141 | 0.86 | RAB9A (0.62) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL25046270 | 0.83 | RAB9A (0.56) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL9749752 | 0.83 | NR3C2 (0.64) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL2643556 | 0.83 | L3MBTL1 (0.55) | ALDH1A1KDM4EL3MBTL1PIK3C3 | |
| SCHEMBL5197796 | 0.82 | MAPT (0.60) | ALDH1A1KDM4ESMN1; SMN2KMT2ANPC1 | |
| SCHEMBL14294323 | 0.82 | NPC1 (0.52) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL22281368 | 0.82 | POLB (0.59) | ALDH1A1KDM4ESMN1; SMN2KMT2ANPC1 | |
| SCHEMBL10276719 | 0.82 | POLB (0.55) | ALDH1A1KDM4ESMN1; SMN2KMT2ANPC1 | |
| SCHEMBL20909676 | 0.81 | NPC1 (0.63) | ALDH1A1KDM4ESMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654043-A | Perovskite precursor liquid, perovskite film, perovskite solar cell and preparation method | 天合光能股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3719012-B1 | N-[4-[(2-AMINO-4-PYRIDINYL)OXY]-3-FLUOROPHENYL]-3-(4-FLUOROPHENYL)-1,2,3,4-TETRAHYDRO-2,4-DIOXO-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AS C-MET/AXL INHIBITORS FOR THE TREATMENT OF TUMORS | MEDSHINE DISCOVERY INC (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | disclosed |
| WO-1996018616-A1 | SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5453512-A | Bromination of acylaminopyridine with 2-acylaminopyridinium hydorbromide | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
| US-5290943-A | Halogenation of pyridine compound | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| WO-1993007141-A1 | HETEROCYCLIC 3-PHENYLPYRROLIDIN-2-ONES, THEIR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| EP-0530524-A1 | Method of producing 2-amino-3-nitro-5-halogenopyridine | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| US-4203988-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-3955918-A | Azo derivatives or pyridine N-oxide for use in hair dye compositions | SOCIETE ANONYME DITE: L'OREAL (FR) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ALDH1A1 4544/4885KDM4E 3961/4885SMN1; SMN2 1945/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | ALDH1A1 2505/4885KDM4E 687/4885SMN1; SMN2 7/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ALDH1A1 3871/4885KDM4E 4219/4885SMN1; SMN2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.